CALR mutations occur in about 20% of patients with primary and post-essential thrombocythemia myelofibrosis, as per the study ...

Cite this: What's Next? Clinical Trials in Myelofibrosis - Medscape - Mar 06, 2025.

While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

The spleen measured 18.2 cm in the craniocaudal ... If this patient had cirrhosis, hepatic fibrosis would be expected to cause both flow resistance leading to portal hypertension and impaired ...

You could pick up germs more easily and feel sicker than usual. As your disease gets worse, your spleen can become enlarged. This can make the area below your ribs on the left side feel painful ...

“The pelabresib and ruxolitinib combination therapy significantly reduced spleen volume – the best prognostic indicator we have at our disposal for long-term myelofibrosis patient outcomes ...